SOURCE: Oragenics, Inc.

April 03, 2007 09:00 ET

Oragenics Wins Phase 1 SBIR Grant for Colorectal Cancer Study

ALACHUA, FL -- (MARKET WIRE) -- April 3, 2007 -- Oragenics, Inc. (AMEX: ONI), a biotechnology development company, announced today that it has been awarded a grant to undertake a clinical research collaboration in the field of colorectal cancer utilizing its proprietary Change Mediated Antigen Technology (CMAT™). The grant, awarded through the Small Business Innovation Research (SBIR) program of the National Cancer Institute (NCI), will support a joint effort by scientists and clinicians at Oragenics and the Lankenau Institute of Medical Research (LIMR) to identify biomarkers of colorectal cancer in early, middle and late stages of the disease.

Dr. Robert Zahradnik, Oragenics' President and CEO, stated, "We are honored by our success in this highly competitive grant process from such a prestigious source as the National Cancer Institute. The high rating given to our application by the scientific review panel shows their enthusiasm for Oragenics' CMAT™ technology."

Dr. Jeffrey Hillman, Oragenics' Chief Science Officer, said, "We are excited by the opportunities offered by the collaboration between our laboratory and LIMR. The data generated will help to increase our general understanding of bowel cancer and, hopefully, will lead to better diagnostic and treatment strategies."

Dr. George C. Prendergast, LIMR President and CEO, added, "This is a promising collaboration which builds on the strengths of both organizations. By combining our expertise, I am confident that this partnership will result in findings which will ultimately benefit cancer patients."

The funded research will use the CMAT™ platform technology to discover genes and proteins that are specifically expressed when healthy bowel cells become cancerous. The discovery of these novel colorectal cancer biomarkers can lead to new ways to diagnose and treat this disease. They also can be used to determine the success or failure of different treatment methods. The Colon Cancer Alliance estimates that one million people are diagnosed with colorectal cancer worldwide each year. In the US, it is the second leading cause of cancer death, underscoring the significant unmet medical need associated with this type of cancer. According to a new study by Kalorama Information, the worldwide market for early cancer detection tests will reach $7.4 billion by 2009, since demand for such tests will continue to increase as new cancer cases soar toward the ten million mark.

About Oragenics

Oragenics, Inc. is a biopharmaceutical company with a pipeline of proprietary technologies. The Company has a number of products in discovery, preclinical and clinical development, with a concentration in two main therapeutic areas, infectious disease and oncology. Our core pipeline includes products for use in the treatment of dental and periodontal infectious diseases, systemic bacterial infections, and for use in weight management. In the discovery stage are three platform technologies for identifying biomarkers of infection, cancer and autoimmune diseases and for the solid-state synthesis of bioactive peptides including small molecule antibiotics.

About the Lankenau Institute for Medical Research

Biomedical researchers and clinical scientists at the Lankenau Institute for Medical Research (LIMR) focus their studies on cancer and heart disease. The goal of our research is to improve prevention, detection, and treatment of these diseases. Our mission is to extend the boundaries of human health through research, technology transfer, and education of our scientific, clinical, business and public communities. LIMR occupies laboratories located on the campus of the Lankenau Hospital, just west of the city of Philadelphia. LIMR is part of Main Line Health, one of the major health care providers in the metropolitan Philadelphia area. LIMR faculty are affiliated with Jefferson Medical School and the Kimmel Cancer Center at Thomas Jefferson University.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect Oragenics' current views with respect to future events and financial performance. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project" and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those set forth in our most recently filed annual report on Form 10-KSB and quarterly report on Form 10-QSB, and other factors detailed from time to time in filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.

Contact Information